EZH2 and neoplasm: Brach et al. also showed that tazemetostat, a EZH2 inhibitor, causes inhibition of tumor growth in both EZH2-mutant (Y646F) and EZH2- DLBCL xenografts due to a loss of H3K27 trimethylation 134.